These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25365085)

  • 21. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
    Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
    Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers in Rheumatoid Arthritis, what is new?
    Gavrilă BI; Ciofu C; Stoica V
    J Med Life; 2016; 9(2):144-8. PubMed ID: 27453744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States.
    Sokka T; Pincus T
    J Rheumatol; 2009 Jul; 36(7):1387-90. PubMed ID: 19411389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
    Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
    Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis.
    Lee DM; Phillips R; Hagan EM; Chibnik LB; Costenbader KH; Schur PH
    Ann Rheum Dis; 2009 Feb; 68(2):201-8. PubMed ID: 18390910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
    BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis.
    Wiacek R; Kolossa K; Jankowski T; Jeka S; Karmowski A; Karmowski M; Gworys B
    Adv Clin Exp Med; 2012; 21(3):337-42. PubMed ID: 23214197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
    Aletaha D; Alasti F; Smolen JS
    Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
    van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypercalcemia and Lytic Bone Lesions Masquerading Inflammatory Arthritis Treated as Rheumatoid Arthritis.
    Salari M; Aboutorabi RB; Rezaieyazdi Z
    Arch Iran Med; 2015 Oct; 18(10):720-3. PubMed ID: 26443255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study.
    Ajeganova S; Andersson ML; Frostegård J; Hafström I
    J Rheumatol; 2013 Dec; 40(12):1958-66. PubMed ID: 23950188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.
    Vastesaeger N; Xu S; Aletaha D; St Clair EW; Smolen JS
    Rheumatology (Oxford); 2009 Sep; 48(9):1114-21. PubMed ID: 19589891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
    Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM
    Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor.
    Yamane T; Hashiramoto A; Tanaka Y; Tsumiyama K; Miura Y; Shiozawa K; Chihara K; Shiozawa S
    J Rheumatol; 2008 Mar; 35(3):414-20. PubMed ID: 18203327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort.
    Mouterde G; Lukas C; Goupille P; Flipo RM; Rincheval N; Daurès JP; Combe B
    J Rheumatol; 2014 Aug; 41(8):1614-22. PubMed ID: 25028372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis.
    Gonzalez SM; Payne JB; Yu F; Thiele GM; Erickson AR; Johnson PG; Schmid MJ; Cannon GW; Kerr GS; Reimold AM; Sokolove J; Robinson WH; Mikuls TR
    J Periodontol; 2015 Feb; 86(2):222-31. PubMed ID: 25299390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests.
    Infantino M; Manfredi M; Meacci F; Sarzi-Puttini P; Ricci C; Atzeni F; Benucci M
    Clin Chim Acta; 2014 Sep; 436():237-42. PubMed ID: 24892812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
    Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
    Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.